Cardlytics, Inc.

Listed Company

CDLXCIK 0001666071NasdaqAcceleratedSmaller ReportingServices-Computer Programming, Data Processing, Etc.DelawareFY ends Dec 31

Period

FY 2025

Revenue

$233.27M

Net Income

$-103.49M

Total Assets

$285.64M

Equity

$-6.51M

Shares Out

57.61M

Op. Cash Flow

$9.29M

CDLX$4.13−69.45% · past yearDBEQ Basic

Daily closing prices

Business

Cardlytics operates a commerce media platform enabling marketers to deliver targeted offers through financial institutions' digital channels and measure sales impact. The Cardlytics platform provides purchase-data-based targeting and closed-loop attribution to consumers via partner banks. The Bridg platform offers identity resolution and customer data analytics using point-of-sale data for merchant insights and marketing. The company serves marketers across industries in the United States and United Kingdom.

Summary from 10-K filed 2026-03-04

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	233	278	309	299	267
Partner Share and other third-party costs	103	128	151	156	141
Delivery costs	26	30	28	30	23
Sales and marketing expense	39	53	57	75	66
Research and development expense	40	50	51	54	38
General and administrative expense	47	56	59	81	66
Acquisition, integration and divestiture costs (benefits)	600,000	200,000	−6	−3	24
Change in contingent consideration	102,000	210,000	1	−128	1
Impairment of goodwill and intangible assets	59	132	71	453	0
Gain (Loss) on Disposition of Business	−5	0	7	0	0
Depreciation and amortization expense	25	26	26	38	30
Total costs and expenses	335	474	445	756	390
Operating loss	−102	−195	−136	−458	−123
Interest expense, net	−8	−6	−2	−3	—
Foreign currency gain/(loss)	6	−1	3	−6	−1
Gain on debt extinguishment	0	13	0	0	—
Total other (expense)/income	−2	6	968,000	−9	−14
Loss before income taxes	−103	−189	−135	−467	−136
Income tax benefit	0	0	0	1	8
Net Loss	−103	−189	−135	−465	−129
Net loss per share, basic (in dollars per share)	−1.95	−3.91	−3.69	−13.92	−3.99
Net loss per share, diluted (in dollars per share)	−1.95	−3.91	−3.69	−13.92	—
Weighted-average common shares outstanding, basic (in shares)	53	48	36	33	32
Weighted-average common shares outstanding, diluted (in shares)	53	48	36	33	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	49	66	92	122	233
Accounts receivable and contract assets, net	83	103	121	116	111
Other receivables	3	4	5	4	6
Prepaid expenses and other assets	3	5	6	8	8
Total current assets	137	178	224	250	359
Property and equipment, net	2	3	3	6	11
Right-of-use assets under operating leases, net	5	6	7	7	10
Intangible assets, net	6	11	35	53	126
Goodwill	110	159	277	353	743
Capitalized software development costs, net	24	33	25	20	13
Other long-term assets, net	1	2	3	3	2
Total assets	286	393	574	691	1,264
Accounts payable	3	4	4	4	5
Accrued compensation	6	5	12	10	12
Accrued expenses	8	7	10	21	20
Partner Share liability	25	32	49	49	47
Consumer Incentive liability	32	46	53	54	53
Contract with Customer, Liability, Current	3	2	2	2	3
Short-Term Debt	0	46	0	—	—
Current operating lease liabilities	2	2	2	5	6
Current contingent consideration	0	−5	−39	−104	−182
Total current liabilities	78	149	171	249	327
Convertible senior notes, net	169	168	228	226	184
Other Long-Term Debt	40	0	30	0	—
Long-term deferred revenue	52,000	0	67,000	334,000	173,000
Long-term operating lease liabilities	5	6	6	4	7
Total liabilities	292	323	439	480	573
Commitments and contingencies (Note 13)	—	—	—	—	—
Common stock	10,000	10,000	9,000	9,000	9,000
Additional paid-in capital	1,400	1,367	1,244	1,183	1,213
Accumulated other comprehensive (loss) income	−2	4	2	6	486,000
Accumulated deficit	−1,404	−1,301	−1,111	−977	−523
Total stockholders (deficit) equity	−7	70	135	212	691
Total liabilities and stockholders (deficit) equity	286	393	574	691	1,264

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Credit loss expense	2	6	2	2	2
Depreciation and amortization	25	26	26	38	30
Amortization of financing costs charged to interest expense	2	2	2	2	968,000
Amortization of right-of-use asset	2	2	3	6	6
Stock-based compensation expense	28	40	41	45	50
Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)	102,000	210,000	1	−128	1
Other non-cash expense (income), net	−6	1	−4	7	1
Accounts receivable and contracts assets, net	21	12	−8	−5	−28
Prepaid expenses and other assets	2	1	2	535,000	−1
Accounts payable	179,000	499,000	239,000	−893,000	1
Other accrued expenses	−724,000	−7	−7	−10	−905,000
Partner Share liability	−8	−16	405,000	2	9
Customer Incentive liability	−8	−7	−1	1	13
Net cash provided by (used in) operating activities	9	−9	−185,000	−54	−39
Acquisition of property and equipment	−480,000	−2	−667,000	−1	−3
Capitalized software development costs	−15	−18	−12	−12	−9
Proceeds from Divestiture of Businesses, Net of Cash Divested	500,000	600,000	2	0	0
Net cash used in investing activities	−15	−19	−10	−16	−507
Proceeds from issuance of debt	56	173	30	0	0
Principal payments of debt	−62	−199	−31,000	−35,000	0
Proceeds from termination of capped calls related to convertible notes	0	100,000	0	0	—
Proceeds from issuance of common stock	0	49	55,000	379,000	486
Settlement of contingent consideration	−5	−14	−50	0	0
Equity issuance costs	0	−309,000	0	−157,000	−190,000
Debt issuance costs	−122,000	−6	0	−174,000	−200,000
Net cash (used in) provided by financing activities	−11	1	−20	−40	486
Effect of exchange rates on cash, cash equivalents and restricted cash	259,000	−110,000	118,000	−2	−567,000
Net decrease in cash, cash equivalents and restricted cash	−17	−26	−30	−112	−60
Cash paid for interest	9	6	4	2	2
Issuance of common stock, net of issuance costs - Settlement Agreement (as defined below)	0	27	0	0	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Cardlytics, Inc.'s CIK number?

Cardlytics, Inc.'s SEC CIK number is 0001666071 (1666071). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Cardlytics, Inc.'s SEC filings?

All of Cardlytics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Cardlytics, Inc. last report earnings?

Cardlytics, Inc. (CDLX) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-032076). This is Cardlytics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Cardlytics, Inc.'s most recent earnings 8-K?

Cardlytics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001628280-26-032076. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Cardlytics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →